Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jenthera Therapeutics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution activity involves 1 distinct examiner and 1 distinct art unit, reflecting a centralized approach to its current patent applications. For practitioners, this means the entirety of the company's active USPTO engagement is focused on a single technical review process.
The busiest examiner for this portfolio is KONOPKA, CATHERINE ANNE, who is currently overseeing 1 busiest examiner pending action. Since the total number of pending office actions is 1, this examiner is responsible for all of the company's active matters. The prosecution strategy for this Biotechnology & Pharmaceuticals portfolio is therefore uniquely dependent on the specific feedback and requirements of this one examiner.
The presence of 1 distinct art unit and 1 distinct examiner indicates that the company is not currently navigating multiple simultaneous examination tracks. While this limits the complexity of managing 1 pending office action, it also focuses the risk on a single point of review. The relationship between the examiner and the pending workload ensures that all current efforts are directed toward resolving this single matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795914 | NUCLEASE-SCAFFOLD COMPOSITION DELIVERY PLATFORM | KONOPKA, CATHERINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17795914 | NUCLEASE-SCAFFOLD COMPOSITION DELIVERY PLATFORM | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17795914 | NUCLEASE-SCAFFOLD COMPOSITION DELIVERY PLATFORM | KONOPKA, CATHERINE ANNE | 1635 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJenthera Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine Anne Konopka has the most, with 1 of Jenthera Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
